medigraphic.com
ISSN 0016-3813 (Impreso)

2002, Número S1

<< Anterior Siguiente >>

Gac Med Mex 2002; 138 (S1)


Trasplante de células progenitoras hematopoyéticas

I. Introducción
II. Criopreservación Celular
III. Trasplante de células progenitoras hematopoyéticas de sangre del cordón umbilical
IV. Enfermedad injerto en contra del hospedero crónica, opciones terapéuticas

Córdova-Caballero MS, Torradadella M, Indrikovs AJ, Gómez-Morales E

Idioma: Español
Referencias bibliográficas: 29
Paginas: 126-134
Archivo PDF: 60.97 Kb.


FRAGMENTO

La médula ósea está constituida fundamentalmente por una red vascular y un conglomerado celular que lo rodea. La red vascular se compone de sinusoides cuya tenue pared está formada por células reticulares sin membrana basal y con sangre en su interior, este lecho vascular representa la vía de comunicación de la médula ósea con el resto del organismo. El conglomerado celular forma el tejido hematopoyético, cada una de las células que lo integran se dividen, al madurar se diferencian y finalmente pasan a la sangre.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Armitage JO. Bone marrow transplantation. N Engl J Med 1994; 330: 827-831.

  2. Haley R, Harvath L, Sugarman J. Ethical issues in cord blood banking: summary of a workshop. Transfusion 1998;38: 863-867.

  3. Broxmeyer HE, Douglas GW, Hangoc G, et al. Human umbilical cord blood as a potencial source of transplantable hematopoyetic stem/progenitor cells. Proc Natl Acad Sci USA 1989;86:3828-3832.

  4. Rubinstein P, Dobrila L, Rosenfield RE et al. Processing and cryopreservation of placental umbilical cord blood for unrelated marrow reconstitution. Proc Natl Acad Sci USA 1989;86:3828-3832.

  5. Rubinstein P, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998;339:1565-77.

  6. Gluckman E, Brxmeyer HE, Auerbach AD et al. Hematopoietic reconstitution cord-blood in a patient with Fanconi’s anemia by means of umbilical cord-blood from an HLA-identical sibling. N Engl J Med 1989;321:1174-1178.

  7. Abdullaev FL, Rivera-Luna R, Roitenburd-Belacourtu V, Espinosa-Aguirre J. Pattern of childhood cancer mortality in Mexico. Arch Med Res 2000;30:526-531.

  8. Food and Drug Administration (FDA). Human tissue intended for transplantation (DocketNo93N-0453). Code of Federal Regulation CFR Title 21 16& 1270.

  9. Ley General de Salud (D.O.F. Reforma. México: 7 de mayo de 1997).

  10. Villalba R, Benítez J, et al. Cryopreservation of human skin with propane-1,2-diol. Cryobiology, 1996;33: 525-529.

  11. Pirnay JP, Hanon P, et al. Ultrarapid freezing: a simple method for skin preservation. European Association of Tissue Banks. 5th International Conference on Tissue Banking; 1996. p. 14.

  12. Organ cryopreservation: current status of research carried out in Grenoble. Prog Urol 1995; 5:927-31; discussion 931-2. (French).

  13. España: Real Decreto 400/1996 sobre aparatos y sistema de protección para uso en atmósferas explosivas. Reglamento Aparatos a Presión, MIE AP-10.

  14. Pegg DE. Viability assays for preserved cells, tissues, and organs. Cryobiology, 26:212-231.19

  15. Rubinstein P, et al. Outcomes among 562 recipients of placental-blood transplants from unrelated donors. N Engl J Med 1998;339:1565-77.

  16. Cairo SM, et al. Placental and/or umbilical cord blood: an alternative source of haematopoietic stem cells for transplantation. Blood 1997;90:4665-78.

  17. Kögler G, et al. The effect of different thawing methods, growth factor combinations and media on the ex vivo expansion of umbilical cord blood primitive and committed progenitors. Bone Marrow Transplant 1998;21:233-41.

  18. Rubinstein P, et al. Processing and cryopreservation of placental/umbilical cord blood for unrelated bone marrow reconstitution. Proc Natl Acad Sci USA 1995;92:10119-22.

  19. Gluckman E. Current status of umbilical cord blood haemato-poietic stem cell transplantation. Exp Hematol 2000; 28:1197-1205.

  20. Wingard JR, Piantadosi S, Vogelsang GB, et al. Predictors of death from chronic graft versus host disease after bone marrow transplantation. Blood 1989;4:1428-1435.

  21. Ferrara JLM, Deeg HJ. Graft versus host disease. New Engl J Med 1991;10:667-674.

  22. Sullivan KM, Goley T, Nims J, et al. Comparison of cyclosporine (CSP), prednisone (PRED) or alternative-day CSO/PRED in patients with standard and high risk chronic graft versus host disease (GVHD). Blood 1993;15 (Suppl 1):215a (Abstract 845).

  23. Gaziev D, Galimberti M, Lucarelli G, Polchi P. Chronic graft versus host disease: is there an alternative to the conventional treatment? Bone Marrow Transplant 2000;25(7):689-696.

  24. Tzakis AG, Abu-Elmagd K, Fung JJ, et al. FK506 rescue in chronic graft versus host disease after bone marrow transplantation. Transplant Proc. 1991; 23: 3225-3227.

  25. Basara N, Blau WI, Romer R, et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 1998; 22:61-65.

  26. Fried RH, Murakami CS, Fisher LD et al. Ursodeoxycholic acid treatment of refractory chronic graft versus host disease of the liver. Ann Intern Med 1992;116:624-629.

  27. Browne PV, Weisdorf DJ, DeFor T, et al. Response to thalidomide in refractory chronic graft versus host disease. Bone Marrow Transplant 2000;26(8):865-870.

  28. Aubin F, Brion A, Deconinck E, et al. Phototherapy in the treatment of cutaneous graft versus host disease. Transplantation 1995;1:151-155.

  29. Sniecinski I, Parker P, Dagis A, et al. Extracorporeal photopheresis (EP) is effective treatment for chronic refractory graft versus host disease (GvHD). Blood 1998;10 (Suppl 1): 454a. (Abstract 1877).




2020     |     www.medigraphic.com